Compensation 990
OrganizationsEmployeesBoard MembersGrantsContractorsTop RankingsPricing

Stay updated on 990 organization compensation

© Civic Register LLC

Compensation 990 is an independent service that uses public IRS Form 990 filings as its source data. We clean and standardize this information, but the original filings may contain errors or omissions. Years on this site refer to the organization’s fiscal year end date on the filing.

About•Report a discrepancy•Your privacy choices
Organizations Diseases, Disorders & Medical Aim at Melanoma

Aim at Melanoma

Fiscal year ending 2024. Filed on July 17, 2025.

3053 Freeport Blvd Suite 222
Sacramento, California 95818

Aim at Melanoma (EIN: 56-2427805) has filed an IRS Form 990 since at least fiscal year 2016. In its fiscal year 2024 IRS Form 990 filing, Aim at Melanoma, a 501(c)(3) charitable organization, reported compensation for 2 out of 10 total employees. Among the employees shown here, the average compensation is $194,141. The highest compensated employee at Aim at Melanoma is Samantha Guild with fiscal year 2024 compensation of $228,274.

Revenue, expenses, and employee compensation

Revenue

$2,971,089

Expenses

$2,329,351

Employee compensation

$893,172
Revenue, expenses, and employee compensation over time

Reported Compensated Employees

Samantha Guild
President and Director
$228,274
$204,500 No related comp$23,774
Alicia Rowell
Vice President
$160,008
$160,008 No related compNo other comp

Benchmark Employee Compensation

Non-Employee Board Members

Howard Maibach
Director
John Kirkwood
Director
Mohammed Kashani-Sabet
Director
Renu Gupta
Director

Mission Statement

AIM AT MELANOMA (AIM) IS GLOBALLY ENGAGED AND LOCALLY INVESTED IN ADVANCING THE BATTLE AGAINST MELANOMA THROUGH INNOVATIVE RESEARCH, LEGISLATIVE REFORM, EDUCATION, AND PATIENT AND CAREGIVER SUPPORT. FOUNDED IN 2004, AIM AT MELANOMA IS THE LARGEST INTERNATIONAL MELANOMA FOUNDATION SEEKING THE CURE FOR MELANOMA. AIM BELIEVES THAT THE CURE FOR MELANOMA WILL BE FOUND MORE QUICKLY BY BRINGING TOGETHER LEADING GLOBAL RESEARCHERS AND FUNDING THEIR COLLABORATIVE RESEARCH. OUR THREE PARADIGM-SHIFTING GLOBAL RESEARCH INITIATIVES, INCLUDING THE MELANOMA TISSUE BANK CONSORTIUM, ARE POISED TO RESHAPE THE FUTURE OF MELANOMA. AIM IS THE RESPECTED VOICE OF MELANOMA ACROSS THE NATION. WHEN DRUGS ARE APPROVED, LEGISLATION IS DRAFTED, AND RESEARCH IS ASSESSED, AIM IS AT THE TABLE, SPEAKING LOUDLY AND CLEARLY ON BEHALF OF PATIENTS AND THEIR FAMILIES. AIM IS THE TRUSTED ADVISOR FOR PHARMACEUTICAL COMPANIES, MEDICAL BOARDS, AND GOVERNMENT AGENCIES ON CRITICAL TOPICS THAT AFFECT MELANOMA PATIENTS.

Revisions to this organization profile

July 17, 2025:
2024 Aim at Melanoma 990 filed
July 19, 2024:
2023 Aim at Melanoma 990 filed
February 9, 2024:
Amended (originally filed June 26, 2023)2022 Aim at Melanoma 990 filed

Get an email when new compensation information is released for Aim at Melanoma

Be the first to know when new IRS Form 990 data is published for this organization.

Related Jobs

View more jobs
Powered by Talroo
Report a discrepancy →